

Financial Results for 3rd Quarter

February 9, 2021

Sumitomo Bakelite Co., Ltd.

1. FY2020 Q3 Financial Result Summary

2. Financial Outlook for FY2020

FY2020 Q3 Financial Result Summary (Y/Y)

【IFRS】

[Unit: Billion yen]

	FY2019	FY2020	Variance	
			(2)-(1)	Ratio(%)
Revenue	157.7	149.0	-8.7	-5.5%
Business Profit	12.4	11.5	-0.8	-6.8%
Operating Profit	11.5	18.6	7.1	61.5%
Profit attributable to owners of parent	10.0	11.8	1.8	18.1%

*"Business profit" is calculated by deducting "Cost of sales" and "Selling, general and administrative expenses" from "Revenue"



*Kawasumi Laboratories Inc. has become a consolidated subsidiary.

The financial results of the subsidiary are included. (Revenue: 5.1 billion yen / Business profit: 0.4 billion yen)

FOREX

JPY / USD	109.10	105.87	-	-
JPY / EUR	121.46	122.30	-	-

Revenue and Business Profit by Business Segment (Y/Y)




Quarterly Revenue by Business Segment

Semiconductor Materials


High Performance Plastics

Quality of Life Products



Analysis of Business Profit (Y/Y)


[Billion yen]



	Sales	Selling & raw material price gap	Fixed cost	FOREX	New consolidation of subsidiaries	Total
Semiconductor Materials	+ 0.8	▲0.3	▲0.1	▲0.1	-	+0.4
High Performance Plastics	▲6.1	+ 0.7	+4.0	+0.0	-	▲1.5
Quality of Life Products	▲1.7	+ 0.3	+1.1	+0.0	+0.4	+0.2
Total	▲7.1	+ 0.7	+5.2	▲0.1	+0.4	▲0.8

Analysis of Business Profit (Q/Q)

[Billion yen]



	Sales	Selling & raw material price gap	Fixed cost	FOREX	New consolidation of subsidiaries	Total
Semiconductor Materials	+ 0.8	+0.1	▲0.1	+0.0	-	+0.8
High Performance Plastics	+2.4	▲0.1	+0.1	+0.0	-	+2.4
Quality of Life Products	+0.7	+ 0.0	▲0.1	+0.0	+0.4	+1.1
Total	+3.9	▲0.1	▲0.1	+0.0	+0.4	+4.2

Financial Outlook for FY2020(Y/Y)

[Unit: Billion yen]


	FY2019	FY2020	Variance	
	(1)	(2)	(2)-(1)	Ratio(%)
Revenue	206.6	206.5	-0.1	-0.1%
Business Profit	14.3	15.0	0.7	4.6%
Profit attributable to owners of parent	9.0	11.0	2.0	22.4%

*"Business profit" is calculated by deducting "Cost of sales" and "Selling, general and administrative expenses" from "Revenue"


*Kawasumi Laboratories Inc. has become a consolidated subsidiary.

The financial results of the subsidiary are included. (Revenue: 10.8 billion yen / Business profit: 0.5 billion yen)

Sales Revenue




Business Profit



Dividends

Dividend: 60.00 yen per share (Interim 30.00yen, Year-end 30.00 yen)

Dividend policy: Stable and continuous dividend payout,
with dividend payout ratio at about 30%



(yen per share)	FY2016	FY2017	FY2018	FY2019	FY2020
Interim	5.00	6.00	37.50	45.00	30.00
Year-end	5.00	6.00	37.50	30.00	30.00
Total	10.00	12.00	75.00	75.00	60.00

* Although we carried out a share consolidation at a ratio of one share for every five shares on 1 October 2018, figures in FY2018 is shown after such share consolidation.

Management Index

		March 2020 [FY2019] Results					March 2021 [FY2020]				
		Q1-Q3 (Apr-Dec) Results				Full Year (Apr-Mar)	Q1-Q3 (Apr-Dec) Results				Full year (Apr-Mar) Forecast
		Q1	Q2	Q3	Total		Q1	Q2	Q3	Total	
		(Apr-Jun)	(Jul-Sep)	(Oct-Dec)		(Apr-Jun)	(Jul-Sep)	(Oct-Dec)			
Earnings per share	(Yen)	83.63	71.19	57.40	212.22	190.96	39.40	27.83	183.38	250.60	233.75
ROA	(%)	6.8	5.8	5.1	5.9	4.0	3.4	2.5	13.0	6.3	5.2
ROE	(%)	8.9	7.6	6.0	7.4	5.0	4.2	2.9	18.8	8.6	6.0
Ratio of equity attributable to owners of parent	(%)	61.4	62.6	62.7	62.7	62.5	62.5	59.6	56.8	56.8	67.3
Capital expenditure	(Billion Yen)	3.1	2.4	2.4	8.0	10.8	2.0	2.5	0.2	6.9	10.0
Depreciation	(Billion Yen)	2.8	2.8	2.9	8.4	11.3	2.8	2.8	0.3	8.9	12.2
R&D expense	(Billion Yen)	2.6	2.6	2.6	7.8	10.3	2.4	2.5	0.3	7.6	10.3
Financial Liability balance at year end	(Billion Yen)	52.3	47.9	50.5	50.5	48.6	52.9	67.5	80.6	80.6	75.4
Net financial income and expenses *	(Billion Yen)	0.4	0.2	0.4	1.0	0.9	0.5	0.1	0.0	0.8	0.8
No. of employees		6,048	6,046	6,017	6,017	5,969	5,865	5,699	8,070	8,070	8,030

*Exclude an effect of loss of investments accounted for using equity method.